Figure 2.

Mice with various chronic inflammatory conditions display enhanced PMN infiltration during zymosan-induced peritonitis. A) DSS-induced colitis. C57BL/6J mice were given 2% DSS in drinking water continuously and development of colitis was monitored by body weight loss, diarrhea, etc, and confirmed by dissection of the colonic tissues. B) STZ-induced type 1diabetes. Mice were consecutively injected with STZ or the vehicle (CTL) for five days. Serum glucose levels were assayed three weeks after the injections. C) Inducing upper respiratory inflammation by LPS. LPS or vehicle was given to mice via the nares every other day for 15 days. The figure shows the histology images (H&E staining) of lung tissue sections after vehicle (Ctl.) or LPS treatment. D–E) Enhanced PMN infiltration in mice with systemic inflammation. Control healthy mice and mice with colitis (DSS for 12days), or hyperglycemia (3 weeks post-STZ treatment) or lung inflammation (LPS) were tested for PMN infiltration by zymosan A-induced peritonitis. Mice received one dose of emulsified CFA (50% in PBS) were also tested in the assay. Panels D and E show the numbers of PMN infiltrated into the peritoneum at 2 h and the kinetics of PMN infiltration into the peritoneum, respectively. The data represent one of eight independent experiments and are expressed as means ± SEM; n=mice number/group. ***, p<0.001, **, p<0.01, versus respective controls.